Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy

Menaka Thounaojam, Annalisa Montemari, Folami Lamoke Powell, Prerana Malla, Diana Raisovna Gutsaeva, Alessandra Bachettoni, Guido Ripandelli, Andrea Repossi, Amany Mohamed Tawfik, Pamela Moore Martin, Francesco Facchiano, Manuela Bartoli

Research output: Contribution to journalArticle

Abstract

We have investigated the contributing role of monosodium urate (MSU) to the pathological processes associated with the induction of diabetic retinopathy (DR). In human postmortem retinas and vitreous from donors with DR, we have found a significant increase in MSU levels that correlated with the presence of inflammatory markers and enhanced expression of xanthine oxidase. The same elevation in MSU levels was also detected in serum and vitreous of streptozotocin-induced diabetic rats (STZ-rats) analyzed at 8 weeks of hyperglycemia. Furthermore, treatments of STZ-rats with the hypouricemic drugs allopurinol (50 mg/kg) and benzbromarone (10 mg/kg) given every other day resulted in a significant decrease of retinal and plasma levels of inflammatory cytokines and adhesion factors, a marked reduction of hyperglycemia-induced retinal leukostasis, and restoration of retinal blood-barrier function. These results were associated with effects of the hypouricemic drugs on downregulating diabetes-induced levels of oxidative stress markers as well as expression of components of the NOD-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome such as NLRP3, Tolllike receptor 4, and interleukin-1b. The outcomes of these studies support a contributing role of MSU in diabetes-induced retinal inflammation and suggest that asymptomatic hyperuricemia should be considered as a risk factor for DR induction and progression.

Original languageEnglish (US)
Pages (from-to)1014-1025
Number of pages12
JournalDiabetes
Volume68
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Diabetic Retinopathy
Uric Acid
Inflammation
Streptozocin
Hyperglycemia
Benzbromarone
Leukostasis
Blood-Retinal Barrier
Interleukin-4 Receptors
Inflammasomes
Hyperuricemia
Allopurinol
Xanthine Oxidase
Pathologic Processes
Pharmaceutical Preparations
Retina
Oxidative Stress
Down-Regulation
Outcome Assessment (Health Care)
Cytokines

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy. / Thounaojam, Menaka; Montemari, Annalisa; Powell, Folami Lamoke; Malla, Prerana; Gutsaeva, Diana Raisovna; Bachettoni, Alessandra; Ripandelli, Guido; Repossi, Andrea; Tawfik, Amany Mohamed; Martin, Pamela Moore; Facchiano, Francesco; Bartoli, Manuela.

In: Diabetes, Vol. 68, No. 5, 01.01.2019, p. 1014-1025.

Research output: Contribution to journalArticle

Thounaojam, Menaka ; Montemari, Annalisa ; Powell, Folami Lamoke ; Malla, Prerana ; Gutsaeva, Diana Raisovna ; Bachettoni, Alessandra ; Ripandelli, Guido ; Repossi, Andrea ; Tawfik, Amany Mohamed ; Martin, Pamela Moore ; Facchiano, Francesco ; Bartoli, Manuela. / Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy. In: Diabetes. 2019 ; Vol. 68, No. 5. pp. 1014-1025.
@article{7177008653aa4a0880fd4f25d070480e,
title = "Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy",
abstract = "We have investigated the contributing role of monosodium urate (MSU) to the pathological processes associated with the induction of diabetic retinopathy (DR). In human postmortem retinas and vitreous from donors with DR, we have found a significant increase in MSU levels that correlated with the presence of inflammatory markers and enhanced expression of xanthine oxidase. The same elevation in MSU levels was also detected in serum and vitreous of streptozotocin-induced diabetic rats (STZ-rats) analyzed at 8 weeks of hyperglycemia. Furthermore, treatments of STZ-rats with the hypouricemic drugs allopurinol (50 mg/kg) and benzbromarone (10 mg/kg) given every other day resulted in a significant decrease of retinal and plasma levels of inflammatory cytokines and adhesion factors, a marked reduction of hyperglycemia-induced retinal leukostasis, and restoration of retinal blood-barrier function. These results were associated with effects of the hypouricemic drugs on downregulating diabetes-induced levels of oxidative stress markers as well as expression of components of the NOD-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome such as NLRP3, Tolllike receptor 4, and interleukin-1b. The outcomes of these studies support a contributing role of MSU in diabetes-induced retinal inflammation and suggest that asymptomatic hyperuricemia should be considered as a risk factor for DR induction and progression.",
author = "Menaka Thounaojam and Annalisa Montemari and Powell, {Folami Lamoke} and Prerana Malla and Gutsaeva, {Diana Raisovna} and Alessandra Bachettoni and Guido Ripandelli and Andrea Repossi and Tawfik, {Amany Mohamed} and Martin, {Pamela Moore} and Francesco Facchiano and Manuela Bartoli",
year = "2019",
month = "1",
day = "1",
doi = "10.2337/db18-0912",
language = "English (US)",
volume = "68",
pages = "1014--1025",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy

AU - Thounaojam, Menaka

AU - Montemari, Annalisa

AU - Powell, Folami Lamoke

AU - Malla, Prerana

AU - Gutsaeva, Diana Raisovna

AU - Bachettoni, Alessandra

AU - Ripandelli, Guido

AU - Repossi, Andrea

AU - Tawfik, Amany Mohamed

AU - Martin, Pamela Moore

AU - Facchiano, Francesco

AU - Bartoli, Manuela

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We have investigated the contributing role of monosodium urate (MSU) to the pathological processes associated with the induction of diabetic retinopathy (DR). In human postmortem retinas and vitreous from donors with DR, we have found a significant increase in MSU levels that correlated with the presence of inflammatory markers and enhanced expression of xanthine oxidase. The same elevation in MSU levels was also detected in serum and vitreous of streptozotocin-induced diabetic rats (STZ-rats) analyzed at 8 weeks of hyperglycemia. Furthermore, treatments of STZ-rats with the hypouricemic drugs allopurinol (50 mg/kg) and benzbromarone (10 mg/kg) given every other day resulted in a significant decrease of retinal and plasma levels of inflammatory cytokines and adhesion factors, a marked reduction of hyperglycemia-induced retinal leukostasis, and restoration of retinal blood-barrier function. These results were associated with effects of the hypouricemic drugs on downregulating diabetes-induced levels of oxidative stress markers as well as expression of components of the NOD-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome such as NLRP3, Tolllike receptor 4, and interleukin-1b. The outcomes of these studies support a contributing role of MSU in diabetes-induced retinal inflammation and suggest that asymptomatic hyperuricemia should be considered as a risk factor for DR induction and progression.

AB - We have investigated the contributing role of monosodium urate (MSU) to the pathological processes associated with the induction of diabetic retinopathy (DR). In human postmortem retinas and vitreous from donors with DR, we have found a significant increase in MSU levels that correlated with the presence of inflammatory markers and enhanced expression of xanthine oxidase. The same elevation in MSU levels was also detected in serum and vitreous of streptozotocin-induced diabetic rats (STZ-rats) analyzed at 8 weeks of hyperglycemia. Furthermore, treatments of STZ-rats with the hypouricemic drugs allopurinol (50 mg/kg) and benzbromarone (10 mg/kg) given every other day resulted in a significant decrease of retinal and plasma levels of inflammatory cytokines and adhesion factors, a marked reduction of hyperglycemia-induced retinal leukostasis, and restoration of retinal blood-barrier function. These results were associated with effects of the hypouricemic drugs on downregulating diabetes-induced levels of oxidative stress markers as well as expression of components of the NOD-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome such as NLRP3, Tolllike receptor 4, and interleukin-1b. The outcomes of these studies support a contributing role of MSU in diabetes-induced retinal inflammation and suggest that asymptomatic hyperuricemia should be considered as a risk factor for DR induction and progression.

UR - http://www.scopus.com/inward/record.url?scp=85065109410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065109410&partnerID=8YFLogxK

U2 - 10.2337/db18-0912

DO - 10.2337/db18-0912

M3 - Article

VL - 68

SP - 1014

EP - 1025

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 5

ER -